News

Back News

EMD-RX5 demonstrates excellent safety and bioavailability in Phase 1 study

EMD-RX5 demonstrates excellent safety and bioavailability in Phase 1 study

Phase One clinical trial results for Emyria’s EMD-RX5 ultra-pure CBD capsules have shown:

– Excellent safety and tolerability
– Equivalent bioavailability to Epidyolex®, the only TGA and FDA-approved medicine on the market
– More stable and predictable drug delivery over time
– Greater bioavailability than other CBD products

Read more about the results here: EMD-RX5 Phase 1 Results – 25 May 22 (weblink.com.au)

Call 08 6559 2800Contact